Serum total adiponectin in nonalcoholic fatty liver disease: A systematic review and meta-analysis

Metabolism: Clinical and Experimental

Volumn 60, Issue 3, 2011, Pages 313-326

  Polyzos, Stergios A ^a   Toulis, Konstantinos A ^a   Goulis, Dimitrios G ^a   Zavos, Christos ^a   Kountouras, Jannis ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN;

ARTICLE; BLOOD LEVEL; DISEASE COURSE; HUMAN; LIVER BIOPSY; LIVER HISTOLOGY; META ANALYSIS (TOPIC); NONALCOHOLIC FATTY LIVER; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RISK FACTOR; SYSTEMATIC REVIEW;

EID: 79951810722     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2010.09.003     Document Type: Review

References (67)

1. Bellentani S, Marino M. Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). Ann Hepatol 2009;8(Suppl 1):4-8.
2. Argo CK, Caldwell SH. Epidemiology and natural history of non-alcoholic steatohepatitis. Clin Liver Dis 2009;13:511-31.
3. Mendez-Sanchez N, Arrese M, Zamora-Valdes D, et al. Current concepts in the pathogenesis of nonalcoholic fatty liver disease. Liver Int 2007;27:423-33. (Pubitemid 46534563)
4. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001;50:1844-50. (Pubitemid 33641605)
5. Polyzos SA, Kountouras J, Zavos C. Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines. Curr Mol Med 2009;72:299-314.
6. Wozniak SE, Gee LL, Wachtel MS, et al. Adipose tissue: the new endocrine organ? A review article. Dig Dis Sci 2009;54:1847-56.
7. Polyzos SA, Kountouras J, Zavos C, et al. The role of adiponectin in the pathogenesis and treatment of nonalcoholic fatty liver disease. Diabetes Obes Metab 2010;12:365-83.
8. Bullen Jr JW, Bluher S, Kelesidis T, et al. Regulation of adiponectin and its receptors in response to development of diet-induced obesity in mice. Am J Physiol Endocrinol Metab 2007;292:1079-86.
9. Matarese G, Mantzoros C, La CA. Leptin and adipocytokines: bridging the gap between immunity and atherosclerosis. Curr Pharm Des 2007;13:3676-80.
10. Ziemke F, Mantzoros CS. Adiponectin in insulin resistance: lessons from translational research. Am J Clin Nutr 2010;91(Suppl 6):258-61.
11. Polyzos SA, Kountouras J, Zavos C. The multi-hit process and the antagonistic roles of tumor necrosis factor-alpha and adiponectin in nonalcoholic fatty liver disease. Hippokratia 2009;13:127.
12. Chandrasekar B, Boylston WH, Venkatachalam K, et al. Adiponectin blocks interleukin-18-mediated endothelial cell death via APPL1-dependent AMP-activated protein kinase (AMPK) activation and IKK/NF-kappaB/PTEN suppression. J Biol Chem 2008;283:24889-98.
13. Nazal L, Riquelme A, Solis N, et al. Hypoadiponectinemia and its association with liver fibrosis in morbidly obese patients. Obes Surg 2010;20:1400-7 [epub ahead of print].
14. Shimada M, Kawahara H, Ozaki K, et al. Usefulness of a combined evaluation of the serum adiponectin level, HOMA-IR, and serum type IV collagen 7S level to predict the early stage of nonalcoholic steatohepatitis. Am J Gastroenterol 2007;102:1931-8. (Pubitemid 47301507)
15. Younossi ZM, Jarrar M, Nugent C, et al. A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obest Surg 2008;18:1430-7.
16. Argentou M, Tiniakos DG, Karanikolas M, et al. Adipokine serum levels are related to liver histology in severely obese patients undergoing bariatric surgery. Obes Surg 2009;19:1313-23.
17. Bugianesi E, Pagotto U, Manini R, et al. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab 2005;90:3498-504. (Pubitemid 41014319)
18. Huang HL, Lin WY, Lee LT, et al. Metabolic syndrome is related to nonalcoholic steatohepatitis in severely obese subjects. Obes Surg 2007;17:1457-63.
19. Hui JM, Hodge A, Farrell GC, et al. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 2004;40:46-54.
20. Kaser S, Moschen A, Cayon A, et al. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 2005;54:117-21. (Pubitemid 40007229)
21. Lemoine M, Ratziu V, Kim M, et al. Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver disease. Liver Int 2009;29:1431-8.
22. Pagano C, Soardo G, Esposito W, et al. Plasma adiponectin is decreased in nonalcoholic fatty liver disease. Eur J Endocrinol 2005;152:113-8. (Pubitemid 40185459)
23. Palekar NA, Naus R, Larson SP, et al. Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease. Liver Int 2006;26:151-6.
24. Wong VW, Hui AY, Tsang SW, et al. Metabolic and adipokine profile of Chinese patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2006;4:1154-61. (Pubitemid 44311653)
25. Jarrar MH, Baranova A, Collantes R, et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2008;27:412-21.
26. Nannipieri M, Cecchetti F, Anselmino M, et al. Pattern of expression of adiponectin receptors in human liver and its relation to nonalcoholic steatohepatitis. Obes Surg 2009;19:467-74.
27. Lesmana CR, Lesmana LA, Akbar N, et al. Clinical picture, insulin resistance, and adipocytokines profiles of nonalcoholic steatohepatitis (NASH) patients in Indonesia. Acta Med Indones 2009;41:6-10.
28. Munoz LE, Cordero P, Torres L, et al. Adipokines in a group of Mexican patients with nonalcoholic steatohepatitis. Ann Hepatol 2009;8:123-8.
29. Polyzos SA, Kountouras J, Zavos C. Adiponectin as a potential therapeutic agent for nonalcoholic steatohepatitis. Hepatol Res 2010;40:446-7.
30. Wilczynski NL, Haynes RB. Robustness of empirical search strategies for clinical content in MEDLINE. Proc AMIA Symp 2002:904-8.
31. Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467-74. (Pubitemid 29420675)
32. Kleiner DE, Brunt EM, Van NM, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-21. (Pubitemid 40770284)
33. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88. (Pubitemid 17189972)
34. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60. (Pubitemid 37088507)
35. Davey SG, Egger M, Phillips AN. Meta-analysis. Beyond the grand mean? BMJ 1997;315:1610-4.
36. Toulis KA, Goulis DG, Farmakiotis D, et al. Adiponectin levels in women with polycystic ovary syndrome: a systematic review and a meta-analysis. Hum Reprod Update 2009;15:297-307.
37. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283:2008-12. (Pubitemid 30214957)
38. Abdelmalek MF, Sanderson SO, Angulo P, et al. Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. Hepatology 2009;50:1818-26.
39. Musso G, Gambino R, Durazzo M, et al. Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease. Hepatology 2005;42:1175-83. (Pubitemid 43112685)
40. Arvaniti VA, Thomopoulos KC, Tsamandas A, et al. Serum adiponectin levels in different types of non alcoholic liver disease. Correlation with steatosis, necroinflammation and fibrosis. Acta Gastro-Enterol Belg 2008;71:355-60.
41. Aygun C, Senturk O, Hulagu S, et al. Serum levels of hepatoprotective peptide adiponectin in non-alcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2006;18:175-80. (Pubitemid 43361603)
42. Gastaldelli A, Harrison SA, Belfort-Aguilar R, et al. Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis. Hepatology 2009;50:1087-93.
43. Haukeland JW, Damas JK, Konopski Z, et al. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol 2006;44:1167-74.
44. Hyogo H, Yamagishi S, Iwamoto K, et al. Elevated levels of serum advanced glycation end products in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2007;22:1112-9. (Pubitemid 47019866)
45. Kitade M, Yoshiji H, Noguchi R, et al. Crosstalk between angiogenesis, cytokeratin-18, and insulin resistance in the progression of non-alcoholic steatohepatitis. World J Gastroenterol 2009;15:5193-9.
46. Sun GX, Tan YJ, Xu C. Relationship between serum adiponectin level and non-alcoholic fatty liver diseases. Acad J Second Mil Med Univ 2008;29:1201-3.
47. Targher G, Bertolini L, Rodella S, et al. Associations between plasma adiponectin concentrations and liver histology in patients with nonalcoholic fatty liver disease. Clin Endocrinol (Oxf) 2006;64:679-83. (Pubitemid 43775007)
48. Targher G, Bertolini L, Rodella S, et al. NASH predicts plasma inflammatory biomarkers independently of visceral fat in men. Obesity (Silver Spring) 2008;16:1394-9. (Pubitemid 351770539)
49. Vuppalanchi R, Marri S, Kolwankar D, et al. Is adiponectin involved in the pathogenesis ofnonalcoholic steatohepatitis?A preliminary human study. J Clin Gastroenterol 2005;39:237-42. (Pubitemid 40283961)
50. Yalniz M, Bahcecioglu IH, Ataseven H, et al. Serum adipokine and ghrelin levels in nonalcoholic steatohepatitis. Mediators Inflamm 2006;2006:34295.
51. Browning JD. New imaging techniques for non-alcoholic steatohepatitis. Clin Liver Dis 2009;13:607-19.
52. Schwenzer NF, Springer F, Schraml C, et al. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol 2009;51:433-45.
53. Adachi M, Brenner DA. High molecular weight adiponectin inhibits proliferation of hepatic stellate cells via activation of adenosine monophosphate-activated protein kinase. Hepatology 2008;47:677-85. (Pubitemid 351280736)
54. Neumeier M, Weigert J, Schaffler A, et al. Aldehyde oxidase 1 is highly abundant in hepatic steatosis and is downregulated by adiponectin and fenofibric acid in hepatocytes in vitro. Biochem Biophys Res Commun 2006;350:731-5. (Pubitemid 44547907)
55. Tilg H, Hotamisligil GS. Nonalcoholic fatty liver disease: cytokine-adipokine interplay and regulation of insulin resistance. Gastroenterology 2006;131:934-45. (Pubitemid 44307061)
56. Jung TW, Lee YJ, Lee MW, et al. Full-length adiponectin protects hepatocytes from palmitate-induced apoptosis via inhibition of c-Jun NH terminal kinase. FEBS J 2009;276:2278-84.
57. Sennello JA, Fayad R, Morris AM, et al. Regulation of T cell-mediated hepatic inflammation by adiponectin and leptin. Endocrinology 2005;146:2157-64. (Pubitemid 40577500)
58. Kadowaki T, Yamauchi T, Kubota N, et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006;116:1784-92. (Pubitemid 44033298)
59. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002;8:1288-95. (Pubitemid 35373562)
60. Bluher M, Brennan AM, Kelesidis T, et al. Total and high-molecular weight adiponectin in relation to metabolic variables at baseline and in response to an exercise treatment program: comparative evaluation of three assays. Diabetes Care 2007;30:280-5. (Pubitemid 46198331)
61. Bianchi G, Bugianesi E, Frystyk J, et al. Adiponectin isoforms, insulin resistance and liver histology in nonalcoholic fatty liver disease. Dig Liver Dis 2010 [epub ahead of print].
62. Cali AM, De Oliveira AM, Kim H, et al. Glucose dysregulation and hepatic steatosis in obese adolescents: is there a link? Hepatology 2009;49:1896-903.
63. Kantartzis K, Staiger H, Machann J, et al. Adiponectin oligomers and ectopic fat in liver and skeletal muscle in humans. Obesity (Silver Spring) 2009;17:390-2.
64. Engl J, Sturm W, Sandhofer A, et al. Effect of pronounced weight loss on visceral fat, liver steatosis and adiponectin isoforms. Eur J Clin Invest 2008;38:238-44. (Pubitemid 351389135)
65. Polyzos SA, Kountouras J, Zavos C. Non-linear distribution of adiponectin in patients with nonalcoholic fatty liver disease limits its use in linear regression analysis. J Clin Gastroenterol 2010;44:229-30.
66. Sohara N, Takagi H, Kakizaki S, et al. Elevated plasma adiponectin concentrations in patients with liver cirrhosis correlate with plasma insulin levels. Liver Int 2005;25:28-32. (Pubitemid 40298241)
67. Tietge UJ, Boker KH, Manns MP, et al. Elevated circulating adiponectin levels in liver cirrhosis are associated with reduced liver function and altered hepatic hemodynamics. Am J Physiol Endocrinol Metab 2004;287:82-9.